Oppenheimer lowered the firm’s price target on Allogene Therapeutics (ALLO) to $7 from $9 and keeps an Outperform rating on the shares. The company closed the ALLO-647 arm of the Phase 2 ALPHA3 study and will not pursue further trials with it after a death, the analyst tells investors in a research note. The firm is more concerned about the death’s impact on trial enrollment than it is about the ramifications of removing ALLO-647 might have on efficacy. However, it still thinks ALPHA3 “is a worthy endeavor that has the potential to be paradigm-changing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event
- Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
- Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment
- Allogene Therapeutics management to meet with Piper Sandler
- Allogene Therapeutics Holds Annual Stockholder Meeting